Table of contents
The Company in 3 lines
- AarogyaAI offers timely detection of DR-TB, allowing patients to be prescribed the most effective drug combinations for treatment.
- The tests are performed to identify the drugs and evaluate whether or not they will work on the patient. It aims to provide affordable services in all remote locations.
- AarogyaAI is also working on testing for other anti-microbial diseases like cholera, which we will see in the company's next phase.
Website: Click here
Social Media Profiles: Facebook, Twitter, Linkedin
Headquarters: Bangalore, India
Business Model: D2C
Founding Year: 2019
Number of Employees: 1-10
Core Team Members: Avlokita Tiwari, Praapti Jayaswal (founders)
Revenue Streams: Treatments, Diagnosis, Patients
Target Market: Remote Locations, Medical Facilities, Patients
Dr. Praapti and Avolkita founded AarogyaAI in 2019. It is headquartered in Banglore. The idea arose from a chaotic system in which the prescription of TB treatment is highly experimental.
There are no techniques for quickly or effectively diagnosing drug-resistant TB. Aarogya AI seeks to identify drug-resistant tuberculosis in a matter of hours. To assist the patient in receiving effective, immediate treatment.
It uploads the patient's DNA sequence to the SaaS. Its machine-learning algorithm then creates a report describing the patient's overall medication resistance status.